This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Fiona Marra on the ZEPATIER® (elbasvir/grazoprevir) DDI profile

Prescribing Information

Fiona Marra, Senior Pharmacist HIV/HCV Lead Pharmacist NHS Scotland

Length: 03:32

The filming was organised and fully funded by MSD, including speaker's honoraria. The views expressed in this presentation are those of the speaker and do not represent the opinions of MSD.

Clinical studies with elbasvir/grazoprevir and pantoprazole showed no clinically relevant effect on elbasvir or grazoprevir exposure. Based on metabolism and clearance a clinically significant interaction is unlikely with Proton Pump Inhibitors (PPIs).1,2

Diabetics may have improved glucose control resulting in symptomatic hypoglycaemia after initiating HCV direct acting antiviral (DAA) treatment. Monitor glucose levels particularly for first 3 months and modify medication if necessary.

Please also see ZEPATIER Summary of Product Characteristics for full list of drug interactions.

C-EDGE CO-STAR: Dore GJ et al. Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons. 2016. Annals of Internal Medicine. STUDY DESIGN: A phase 3, randomised, parallel-group, double-blind, placebo-controlled study in G1, G4 and G6* treatment-naïve patients receiving OST for at least 3 months, with or without compensated cirrhosis. Patients (n=201) received ZEPATIER (immediate treatment arm) or placebo (deferred treatment arm) (n=100) for 12 weeks. Primary endpoint SVR12 (HCV RNA<15 IU/ml). Receiving Opioid Agonist Therapy.

* ZEPATIER is not licensed to treat patients with G6 infection.

More information about ZEPATIER:

References

  1. ZEPATIER Summary of Product Characteristics.
  2. University of Liverpool HEP Drug Interaction Checker: https://www.hep-druginteractions.org/checker.

Supporting documentation

GB-ZEP-00111 | Date of Preparation: June 2019